The home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea ...

Resmed (RMD) announced its home sleep apnea test, NightOwl, is now available across the United States. NightOwl is an FDA-cleared home sleep ...

NightOwl is now widely available across the United States. Individuals interested in NightOwl should speak with their healthcare provider for more information. To learn more, visit: https://www.resmed ...

NightOwl, an FDA-cleared home sleep apnea test (HSAT) offers a simplified, accurate, efficient way to diagnose obstructive sleep apnea (OSA). It adds another offering to Resmed’s portfolio, which is ...

We recently published a list of Jim Cramer is Discussing These 10 Stocks Ahead of Q1 Earnings Season. In this article, we are ...

RMD recently launched its home sleep apnea test, NightOwl, across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT), designed to offer healthcare providers a simplified, ...

Leading health technology, Resmed, has announced its home sleep apnea test, NightOwl, is now available across the United ...

Which is the better option for ASX investors, Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) or ResMed Inc. (ASX: RMD) ...

Use of positive airway pressure therapy decreased the risk for all-cause and cardiovascular mortality in adults with ...

This review included 30 studies to analyze the potential for prolonged life in patients who use CPAP to treat obstructive sleep apnea.

Jim Cramer said in a latest program on CNBC that he likes Resmed Inc. (NYSE:RMD), which makes treatments for sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions.